Press releases
12.05.14
Gene Signal announces positive data from Phase III trial of aganirsen eye drops for corneal neovascularisation due to inflammation, a rare eye disease with European Orphan Drug designation
ENG / FRA / DEU
10.04.14
Gene Signal announces publication of positive results from Phase IIa study of topical aganirsen in psoriasis
ENG / FRA
23.01.13
Gene Signal announces completion of private funding round
Company set to embark on aggressive three-year clinical and commercialisation plan for angiogenesis therapies
ENG / FRA / DEU
08.05.12
Gene Signal Presents Positive Data at ARVO 2012 Demonstrating Topical Aganirsen is Active in Models of Retinal Neovascular disease
ENG
14.02.12
Topical Aganirsen Shows Efficacy in AMD and Ischemic Retinopathy Models
ENG
07.07.11
Expert Ophthalmology Panel Releases Consensus Statement on the Management of Corneal Diseases associated with Neovascularisation
ENG / DEU
01.07.10
Results of a Meta-Analysis Show Neovascularization Increases Risk for Corneal Transplant Rejection and Failure
ENG / FRA
01.09.09
Gene Signal and Collaborators Publish GS-101 Clinical Data Suggesting Safe and Effective Inhibition of Abnormal Ophthalmic Blood Vessel Growth
ENG / FRA / DEU / ESP /
11.08.09
Gene Signal Announces Publication of Phase I Data Highlighting Safety of GS-101 for Diseases of the Eye
ENG
11.11.08
Gene Signal enters Phase III Clinical Tests for the prevention of Corneal Graft Rejection
ENG / FRA / DEU